Proposers Conference

Solicitation Number: RPP-26-10-RAPID

“Rapid Antibody Production for Immunoassay Diagnostics”

April 27, 2026

Objectives

- What is the RRPV?
- What is an OTA?
- Highlight key aspects of the Request for Project Proposals
- Provide a deeper understanding of technical requirements
- Teaming Connect

What is the RRPV?

The **Rapid Response Partnership Vehicle (RRPV)** is a public-private partnership that supports the **Biomedical Advanced Research and Development Authority (BARDA)** in accelerating the development of **medical countermeasures (MCMs)**.

Through RRPV, BARDA can rapidly engage industry and academia to develop solutions that address evolving public health threats, including:

- Pandemic influenza
- Emerging infectious diseases
- Other biological threats

Key Focus Areas

Medical Technology (MedTech)

Vaccines & Therapeutics (Vx/Tx)

Medical Countermeasure Clinical Research Centers (MCCRC)

What is an OTA?

An Other Transaction Agreement (OTA) is a flexible partnership mechanism that enables the federal government to rapidly collaborate with industry to develop innovative technologies.

Why OTAs Matter

- Faster and more flexible that traditional FAR-based contracts
- Reduced acquisition regulatory burden enables rapid innovation
- Designed for collaboration between government, industry, and academia

The RRPV OTA

- Advances research and development of medical countermeasures
- Engages nontraditional partners and cutting-edge technologies
- Supports rapid response to public health emergencies

Objectives

What is the RRPV?

What is an OTA?

Highlight key aspects of the Request for Project Proposals

Provide a deeper understanding of technical requirements

Teaming Connect

Caution

The **RRPV-26-10-RAPID** Request for Project Proposals (RPP) is the official source of information regarding the active solicitation.

If you act on information from any source other than these official sources, it is at your risk.

RRPV membership is required for the submission of an abstract in response to this RPP.

To join RRPV, visit www.rrpv.org/how-to-join

Request for Project Proposals (**RPP**)



Biomedical Advanced Research and Development Authority (BARDA)

Rapid Response Partnership Vehicle (RRPV)

Request for Project Proposals (RPP)

Solicitation Number: RRPV 26-10-RAPID

"Rapid Antibody Production for Immunoassay Diagnostics"

Request Issue Date: 15 APRIL 2026
Due Date: 13 MAY 2026 by 1pm Eastern

Biomedical Advanced Research and Development Authority (BARDA)
Contracts Management & Acquisition (CMA)
400 7th Street, SW, Washington, DC 20024
MedicalCountermeasures.gov

BARDA

RPP can be found on the RRPV website:
https://www.rrpv.org/opportunities/

Funding Plan and Period of Performance

- **Sponsor:** BARDA
- **Funding Available: Approximately $15M-20M**
- **Anticipated Number of Awards: 5 to 6 awards**
- **Period of Performance (PoP): 24 months anticipated, may extend beyond**
- **Cost Sharing:** Cost sharing is defined as the resources expended by the Project Awardee on the proposed Statement of Work (SOW). Cost sharing is encouraged, if possible, as it leads to stronger leveraging of Government-Performer collaboration but is not required

Timeline



Abstracts must be submitted to the RRPV BDR Portal at: rrpv.hhs.gov

Required Submission Documents (2)

Abstract – 5-page limit

(See Attachment 1 of RPP for template)

Includes:

- Cover page (not included in page count, 1-page limit)
- Executive Summary
- Technical approach narrative with preliminary data
- Teaming/subcontractors
- Facilities and personnel qualification
- Period of performance and high-level schedule breakdown for key tasks (not included in page count, 0.5-page limit)
- Budget estimation (not included in page count, 0.5-page limit)
- Data Rights Assertions (as needed, not included in page count)

Quad Chart – 1-page limit

(See Attachment 1 of RPP for template)

- Includes objective, description of effort, benefits of proposed technology, challenges, maturity of technology, picture/graphic that illustrates research/concept, bullet list of major/goals milestones

Evaluation

The Government will conduct an evaluation of all qualified abstracts after the preliminary completeness screening by the CMF:

Evaluation Factors

1. Relevance to SOO
2. Innovation/Technical Merit (High-level only)
3. Feasibility (General only)
   a) Confidence in approach
4. Potential impact or benefit
5. Rough budget estimate

Given the limited page-count, the evaluation of Stage 1 Abstracts will be primarily focused on the Technical Approach. Offerors must include all elements in the provided template but are recommended to emphasize a clear Technical Approach supported by preliminary data.

Evaluation Outcome

1. Feedback and invitation to proceed to Stage 2 ((Full Technical Proposal and Cost Proposal) provided
2. Notification that abstract placed in Basket
3. Notification that not selected to proceed to Stage 2

Request a BDR RRPV Portal Account

In order to submit an abstract, an account is REQUIRED. ATI is not able to accept submissions by any other method.

Request Access to the BDR RRPV Portal by filling out the BDR RRPV Portal Access Request form linked on the RRPV.org site.

https://atisc.formstack.com/forms/bdr_rrpv_portal_access_request

Request a BDR RRPV Portal Account

BDR Portal Information

***IMPORTANT* - Accounts with no activity for 60 days are automatically deactivated.**

- If you have an account, log in and make sure it is still active a few days before you intend to submit.
  - *If deactivated, send an email to RRPV@ati.org to reactivate.*
- If you do not have a BDR account, submit your request several days before the close of the RPP.

Objectives

What is the RRPV?

What is an OTA?

Highlight key aspects of the Request for Project Proposals

Provide a deeper understanding of technical requirements

Teaming Connect

Overall RAPID Program Goals

- Establish an US-based rapid and adaptable antibody/protein binder production capability
- Platforms will significantly accelerate design/discovery through delivery of high-performance binders to Dx developers to enhance readiness
- Platforms will be adaptable and capable of generating high-performance binders to known or previously unknown biological threats.

Two Phases in the Base Program

BASE: Phase 1- Concept Demonstration:

- R&D work, process development, and demonstration of the integrated platform.
- Phase 1 Capstone will be a pressure-test where offerors will produce antibody/binders against USG selected organisms/infectious agents (three BSL2 target genomes; viruses, bacteria, and/or fungi).
- Functional performance will be evaluated against a standard assay format (e.g. ELISA; further information in Stage 2 invitation)
    - Performance will be compared across all teams, binder performance* > delivery time.

**target specific performance metrics will be disclosed with challenge target(s) during the performance of the program.*

Two Phases in the Base Program

BASE: Phase 2 – Sprint Test:

- Full speed sprint test against a USG selected target (likely BSL3)
- Final performance will be verified by a third party on a standard assay format (e.g. ELISA).
- Performance metrics will be provided upon disclosure of challenge target(s) at the beginning of the sprint test.

Stage 1 abstracts should NOT address potential options.

Preferred Product Solutions

- **Rapid binder generation platforms for immunoassays**
  - MUST be integrated end-to-end solutions; Binder design/discovery → optimization → production
  - MUST be capable of generating antibody or protein-based binders for viral, bacterial, or fungal pathogens.
  - MUST be capable of responding to threats direct from the genome sequence.
  - SHOULD significantly reduce time to deliver high-performance purified reagents to Dx developers. Ideally within weeks.
  - *Nucleic-acid based binder (e.g. aptamers) are NOT IN SCOPE.*
- **Platforms should incorporate advanced design and discovery capabilities**
  - E.g., Computational and AI-enabled approaches, High-throughput screening
  - Priority is speed, all solutions that significantly decrease delivery time of high-performance binders are welcome
- **Production approaches must focus on capabilities/scale needs for Dx**
  - Priority is production and purification of binders for diagnostic use in compressed timelines

Out of Scope Areas

Following topics will be considered out of scope:

- Development of complete diagnostic devices or commercial test kits
- Clinical validation studies or regulatory submission activities
- Programs targeted toward vaccine or therapeutic antibody development
- Nucleic acid-based binders (e.g., aptamers)

Objectives

- What is the RRPV?
- What is an OTA?
- Highlight key aspects of the Request for Project Proposals
- Provide a deeper understanding of technical requirements
- Teaming Connect

Questions and Answers

- Please enter your questions into the Q&A box.
- Responses to questions received during the Proposer's Conference will be posted shortly after webinar.
- Submit any other RPP-related questions by April 30, 12:00pm ET to:
  - Ms. Kathy Garee (RRPV-contracts@ati.org)